neoantigen nanovaccine

A **neoantigen nanovaccine** is a personalized cancer immunotherapy formulation that delivers tumor-specific neoantigens (peptides generated from tumor-specific mutations) via a nanoparticle platform to induce potent anti-tumor immune responses. These vaccines are custom-designed for each patient by identifying tumor mutations, predicting immunogenic neoepitopes, and synthesizing corresponding peptides, which are coupled to nanoparticle carriers. The nanoplatform typically incorporates immunostimulatory adjuvants (such as STING agonists), targeting peptides, and may use delivery vehicles such as liposomes, polymeric nanoparticles, dendritic cell-derived exosomes, or hydrogels. The main mechanism is to enhance antigen uptake by dendritic cells, cross-presentation to T cells, activation of both CD4+ and CD8+ T lymphocytes, and modulation of the tumor microenvironment to overcome immune suppression. Combination with immune checkpoint inhibitors (such as anti-PD-1 antibodies) has shown improved efficacy. The approach has demonstrated immunogenicity and signs of clinical benefit in early trials, especially in cancers such as pancreatic cancer, melanoma, and breast cancer[1][3][4].

Brand names

neoantigen nanovaccine

Other names

personalized neoantigen nanovaccinenanovaccine containing neoantigennAg-MRDE/Mnneoantigen nanovaccine immunotherapy